Avoro Capital Advisors LLC: APELLIS PHARMACEUTICALS INC (APLS): Quarterly 13F Position History
As of Q1 2026, Avoro Capital Advisors LLC reported 12,222,222 shares of APELLIS PHARMACEUTICALS INC (APLS), worth $491.7M and representing 4.8% of its 13F equity book. The position first appeared in Q4 2017 and has been disclosed across 34 13F-HR filings in Pactolio's tracked window.
- 12,222,222Shares Held (Latest Filing)
- $491.7MReported Market Value (Latest Filing)
- 4.8%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$184.7MQuarter-over-Quarter Value Change
- 12,222,222Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 34 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 12,222,222 | 0 | — | $491.7M | 4.8% | $40.2 |
| Q4 2025 | 12,222,222 | 0 | — | $307.0M | 3.0% | $25.1 |
| Q3 2025 | 12,222,222 | 0 | — | $276.6M | 3.6% | $22.6 |
| Q2 2025 | 12,222,222 | 0 | — | $211.6M | 3.7% | $17.3 |
| Q1 2025 | 12,222,222 | 0 | — | $267.3M | 4.2% | $21.9 |
| Q4 2024 | 12,222,222 | +1,111,111 | +10.0% | $390.0M | 5.5% | $31.9 |
| Q3 2024 | 11,111,111 | 0 | — | $320.4M | 4.7% | $28.8 |
| Q2 2024 | 11,111,111 | 0 | — | $426.2M | 5.7% | $38.4 |
| Q1 2024 | 11,111,111 | 0 | — | $653.1M | 7.6% | $58.8 |
| Q4 2023 | 11,111,111 | 0 | — | $665.1M | 9.2% | $59.9 |
| Q3 2023 | 11,111,111 | 0 | — | $422.7M | 6.6% | $38.0 |
| Q2 2023 | 11,111,111 | 0 | — | $1.0B | 13.7% | $91.1 |
| Q1 2023 | 11,111,111 | +486,111 | +4.6% | $732.9M | 10.9% | $66.0 |
| Q4 2022 | 10,625,000 | +500,000 | +4.9% | $549.4M | 8.2% | $51.7 |
| Q3 2022 | 10,125,000 | +320,000 | +3.3% | $691.5M | 12.8% | $68.3 |
| Q2 2022 | 9,805,000 | +355,000 | +3.8% | $443.4M | 8.8% | $45.2 |
| Q1 2022 | 9,450,000 | +894,445 | +10.5% | $480.2M | 8.8% | $50.8 |
| Q4 2021 | 8,555,555 | +3,555,555 | +71.1% | $404.5M | 6.9% | $47.3 |
| Q3 2021 | 5,000,000 | +3,994,770 | +397.4% | $164.8M | 2.6% | $33.0 |
| Q2 2021 | 1,005,230 | +5,230 | +0.5% | $63.5M | 1.1% | $63.2 |
| Q1 2021 | 1,000,000 | +1,000,000 | — | $42.9M | 0.7% | $42.9 |
| Q4 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2018 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2018 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2018 | 0 | 396,635 | -100.0% | $0 | 0.0% | — |
| Q1 2018 | 396,635 | 0 | — | $7.5M | 0.4% | $18.8 |
| Q4 2017 | 396,635 | — | — | $7.3M | 0.5% | $18.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a APLS position in 13F-HR filings?
Avoro Capital Advisors LLC first reported APELLIS PHARMACEUTICALS INC (APLS) on its 13F-HR filing for the period ending 2017-12-31 (Q4 2017). The position has appeared on 34 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in APLS?
Avoro Capital Advisors LLC held the same 12,222,222 shares of APLS between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in APLS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.